PneumoniaNCT05926089
Acute Phase Reactant in Non-COVID-19 Bacterial Pneumonia
An observational study of Pneumonia and Acute-Phase Reaction, run by Cairo University at 1 site in Egypt.
Trial summary
This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021. The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Pneumonia, Acute-Phase Reaction
- What is being tested?
- Blood sampling
- How many people
- 51 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2020to 30 May 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients( 51 patients diagnosed as non-COVID19 Pneumonia) were subjected to: 1. Full historywith emphasis on: * Epidemiological features . * Risk factors (smoking, DM). * Clinical presentation (cough, Fever and duration of ilness). 2. Clinical examination (local chest examination). 3. Laboratory investigations: venous blood samples were taken for:• Complete blood picture, differential leucocytic count and platelets count, ESR ,CRP, d-dimer and ferritin
Who may be able to join
- COVID-19 negative bacterial pneumonia
Who cannot join
- COVID-19 positive
- other non-pulmonary infections
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Acute Phase Reactant in Non-COVID-19 Community Acquired Pneumonia
This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021.
The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR and the disease severity.
Read the detailed description
51 patients were included in our study, diagnosed as Non-COVID pneumonia
Inclusion criteria:
- PCR(polymerase chain reaction) negative for COVID.
- All patients of both sexes with pneumonia .
Exclusion criteria:
- Non pulmonary infections.
- Post surgery patients.
- Renal patients.
- hepatic patients.
- Cardiac patients.
- Recent pulmonary embolism.
Methodology in details:
All patients were subjected to:
- Full history with emphasis on:
- Epidemiological features (age, gender).
- Risk factors (smoking, DM).
- Clinical presentation (cough, Fever and duration of illness).
- Clinical examination (local chest examination).
- Laboratory investigations: venous blood samples were taken to measure APR
- Conditions
- Pneumonia, Acute-Phase Reaction
- Being tested
- Blood sampling
- Medical subject headings
- Pneumonia, Acute-Phase Reaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood samplingDiagnostic test
blood sampling to measure APR
What is being measured
The primary outcome is the main question the study is designed to answer.
measurement of APR levels in non-Covid-19 pneumonia
assessment of the level of APR and its relation to disease severity
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2023
- Study start1 Oct 2020
- Primary completion30 Apr 2021
- Study completion30 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eman Kamal Ibrahim Hassan, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05926089
- Sponsor's protocol ID
- MS-358-2020
- Status last verified
- Jul 2023
- First submitted
- 28 Jun 2023
- Last updated
- 14 Jul 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acute Phase Reactant in Non-COVID-19 Community Acquired Pneumonia
- ClinicalTrials.gov ID
- NCT05926089
- Acronym / sponsor ID
- MS-358-2020
- Conditions
- Pneumonia, Acute-Phase Reaction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Oct 2020 (actual)
- Primary completion
- 30 Apr 2021 (actual)
- Study completion
- 30 May 2021 (actual)
- First posted
- 3 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a cross-sectional study, was conducted at Chest department of Kasr Al-ainy Hospital, Cairo university during the period between October 2020 and April 2021.
The aim of the work was to evaluate levels of acute phase reactants(APR) in Non-COVID-19 bacterial pneumonia, and to correlate between levels of APR and the disease severity.
Detailed description
51 patients were included in our study, diagnosed as Non-COVID pneumonia
Inclusion criteria:
- PCR(polymerase chain reaction) negative for COVID.
- All patients of both sexes with pneumonia .
Exclusion criteria:
- Non pulmonary infections.
- Post surgery patients.
- Renal patients.
- hepatic patients.
- Cardiac patients.
- Recent pulmonary embolism.
Methodology in details:
All patients were subjected to:
- Full history with emphasis on:
- Epidemiological features (age, gender).
- Risk factors (smoking, DM).
- Clinical presentation (cough, Fever and duration of illness).
- Clinical examination (local chest examination).
- Laboratory investigations: venous blood samples were taken to measure APR
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients( 51 patients diagnosed as non-COVID19 Pneumonia) were subjected to: 1. Full historywith emphasis on: * Epidemiological features . * Risk factors (smoking, DM). * Clinical presentation (cough, Fever and duration of ilness). 2. Clinical examination (local chest examination). 3. Laboratory investigations: venous blood samples were taken for:• Complete blood picture, differential leucocytic count and platelets count, ESR ,CRP, d-dimer and ferritin
Key inclusion criteria (1 listed)
- COVID-19 negative bacterial pneumonia
Key exclusion criteria (2 listed)
- COVID-19 positive
- other non-pulmonary infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood samplingblood sampling to measure APR | Diagnostic test | – |
Primary outcome
measurement of APR levels in non-Covid-19 pneumonia
Time frame: 6 months
assessment of the level of APR and its relation to disease severity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2023.
- Individual participant dataSharing planned: No
Related trials for Pneumonia
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Chronic Graft-versus-host-disease
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia and Acute-Phase Reaction, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
measurement of APR levels in non-Covid-19 pneumonia (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2023.